TB-ST RAPID TEST FOR TUBERCULOSIS DIAGNOSIS IN A RESOURCE POOR SETTING: ARE CASES OF TUBERCULOSIS GOING UNDIAGNOSED?

doi:10.1136/thx.2010.151043.16

N Javanshir, D S Shah, D E Jennings, J Ivaný, H J Milburn. 1GKT School of Medicine, King’s College, London, UK; 2Clinical and Diagnostic Sciences, King’s College, London, UK; 3Dept Respiratory Medicine, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

Introduction Diagnosis of tuberculosis (TB) ideally involves culture and sensitivity of the organism but in low income countries this is not practised routinely. The World Health Organisation estimates that substandard detection occurs in 40% of patients globally, with many diagnosed on clinical suspicion or response to medication. TB produces a strong antibody response suitable for simple, inexpensive and rapid serodiagnostic assays. Ongoing evaluation of a new point of care rapid serological test based on lateral flow immunochromatography (TB-ST Rapid Test, Lionex, Germany) has shown 100% specificity, with no false positive tests in normal controls and latentely infected patients, but sensitivity of 36%, with false negatives in culture proven TB.

Aim Using this test in a resource poor setting to investigate whether cases of active TB may be being missed by current diagnostic methods.

Methods 498 patients in chest and HIV clinics in two rural Kenyan hospitals were investigated with the TB-ST Rapid Test and a scored questionnaire to determine symptoms and risk of TB. Results were compared with clinical diagnoses made, usually based on symptoms alone. Chest radiographs were performed in only 111 and sputum smears in 75.

Results 127/498 patients were HIV positive. Of these, only 59 (46%) had a clinical diagnosis of TB, whereas 68 (54%) had significant TB symptoms and/or risk factors, and 82 (64.6%) tested TB-ST positive (p<0.001). Therefore clinical diagnosis accounted for significantly fewer diagnoses of active TB than suggested by either symptom and risk score or TB-ST rapid results in the HIV+ population. Of the 375 HIV− patients, 73 (19.7%) had a clinical diagnosis of TB, 46 (12.3%) scored positive for TB on the questionnaire, and 149 (40.2%) were TB-ST+ (p<0.001). Abstract P165 Table 1 shows positive and negative TB-ST results related to positive and negative sputum smears in 34 HIV+ and 41 HIV− patients.

Conclusion In contrast with other TB disease types, QFT screening in contacts of smear positive pulmonary TB does not identify contacts for chemoprophylaxis, but rather identifies contacts that we may choose not to treat.

Abstract P165 Table 1

<table>
<thead>
<tr>
<th>Progression risk % (SEM)</th>
<th>Group A</th>
<th>Group B</th>
<th>Group C</th>
</tr>
</thead>
<tbody>
<tr>
<td>0−365</td>
<td>11.7 (4.0)</td>
<td>5.7 (2.0)</td>
<td>1.0 (1.0)</td>
</tr>
<tr>
<td>365−730</td>
<td>15.2 (4.0)</td>
<td>7.4 (3.0)</td>
<td>2.0 (1.0)</td>
</tr>
</tbody>
</table>

CHARACTERISATION OF TUBERCULOUS MEDIASTINAL LYMPHADENOPATHY ON CT AND CORRELATION WITH BIOMARKERS AND CHEST RADIOGRAPH FINDINGS

doi:10.1136/thx.2010.151043.18

A Singanayagam, P George, D Connell, S Kaneria, J Dharwal, P Molyneaux, M Wickremaasinghe, A Lalvani, A Wright, O M Kon. St Mary’s Hospital, London, UK

Introduction The aim of this study was to characterise the anatomical pattern of mediastinal lymphadenopathy on CT in active tuberculosis (TB) and assess correlation with biomarkers and chest radiograph (CXR) findings.

Methods We conducted a retrospective analysis of patients treated for active TB with mediastinal lymphadenopathy at a tertiary centre between January 2007 and May 2009. CT scans performed prior to commencement of therapy were reviewed by two radiologists to assess for pathologically enlarged lymph nodes (LN) (short axis diameter >1.0 cm) at each of the LN stations defined by the International Association for the Study of Lung Cancer (IASLC).

Results 55 patients were included in the study. 56.3% of enlarged LNs were right sided, 32.9% were in central LN groups and 10.8% were left sided. 40.0% of patients had evidence of necrosis within LNs. The most frequently occurring enlarged LNs were in the

INTERFERON GAMMA RELEASE ASSAYS ARE RECOMMENDED FOR SCREENING CLOSE CONTACTS OF PATIENTS WITH ACTIVE TUBERCULOSIS

doi:10.1136/thx.2010.151043.17

P Haldar, H Thurasingham, H Patel, W Hoskins, G Wolthmann. University Hospitals of Leicester, Leicester, UK

Introduction Interferon gamma release assays (IGRAs) are recommended for screening close contacts of patients with active tuberculosis (TB) in the UK. Compared with tuberculin skin testing, greater specificity with IGRAs reliably informs the need for chemoprophylaxis in screened contacts by identifying latent Mycobacterium tuberculosis infection (LTBI) associated with a high risk of secondary disease progression. However, the risk of secondary progression varies with the nature of disease in the primary case and is greatest for contacts of smear positive pulmonary disease. The role of IGRAs in this very high risk population is not clear.

Aim To evaluate the benefit of screening with QuantiFERON®-TB Gold (QFT) in contacts of smear positive pulmonary TB.

Methods A prospective observational study. We have offered QFT based single step screening programme for all close contacts of smear positive pulmonary TB since January 2007. We present 2-year follow-up data in tested and untested contacts that did not receive chemoprophylaxis. Secondary disease risk is estimated with Kaplan—Meier analysis and subgroups compared with the log-rank test.

Results 576 recorded contacts for 92 smear positive cases. Median follow-up 698 days (range 287−1146 days). 467 (81.1%) of contacts were QFT screened. 36% of tested contacts had a positive QFT, 85 QFT positive contacts did not receive chemoprophylaxis (group A); 101 contacts were not screened and untreated (group B); 301 were QFT negative (group C). Secondary disease occurred in 22 contacts (11 group A, 5 group B). Progression rates at 12 and 24 months are shown (Abstract P166 Table 1). Compared with the untested subgroup, a positive QFT result did not significantly increase progression risk (RR 2.1 (95% CI 0.7 to 5.9), p=0.13). A negative QFT result did significantly lower progression risk (RR 0.28 (95% CI 0.09 to 0.82) at 2 years, p=0.01). The negative predictive value of QFT compared with not testing was 93.2% (95% CI 85.8 to 97.5).

Abstract P166 Table 1

<table>
<thead>
<tr>
<th>Observation period/days</th>
<th>Group A</th>
<th>Group B</th>
<th>Group C</th>
</tr>
</thead>
<tbody>
<tr>
<td>0−365</td>
<td>11.7 (4.0)</td>
<td>5.7 (2.0)</td>
<td>1.0 (1.0)</td>
</tr>
<tr>
<td>365−730</td>
<td>15.2 (4.0)</td>
<td>7.4 (3.0)</td>
<td>2.0 (1.0)</td>
</tr>
</tbody>
</table>